Welcome to our dedicated page for Spectral AI news (Ticker: $MDAI), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Spectral AI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Spectral AI's position in the market.
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13-14, 2024. The company will host investor meetings during the conference, offering an opportunity for virtual or in-person meetings. This event aims to showcase Spectral AI's focus on medical diagnostics for wound care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.67%
Tags
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announced a Letter to Shareholders detailing the Company's progress towards commercializing its AI-driven DeepView System for wound assessment and treatment. The letter highlights a $149 million contract from BARDA, revenue generation expectations, FDA and UKCA marking for proprietary technology, promising interim results for DFU Clinical Study, and new management appointments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
-
Rhea-AI Summary
Spectral MD, Inc. announces the submission of an application in the UK for its predictive software DeepView AI®-Burn to be registered as UK Conformity Assessed for burn wound use. This marks a significant step towards commercialization for the company's AI software in the medical diagnostics field, specifically for thermal burn wounds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
Rhea-AI Summary
Spectral AI, Inc. (MDAI) announces the enrollment of the first patient in the pivotal study to validate DeepView AI® for burn size and healing assessment. The study is expected to be the final clinical trial before seeking FDA marketing authorization in 2025. The company continues to utilize $251 million of non-dilutive government funding since 2019 to validate DeepView for burn indication and other clinical indications like diabetic foot ulcers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
-
News
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) has announced the hiring of Peter M. Carlson as Chief Financial Officer. Carlson brings a strong track record in senior financial executive roles at public companies, including healthcare entities, and will play a crucial role in navigating the financial landscape and strategic opportunities for Spectral AI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.23%
Tags
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) is an AI company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care. The company announced its participation in the Benchmark 12th Annual Discovery One-on-One Conference in New York City. Spectral AI's DeepView® System has received a significant contract from the U.S. Government and has been validated through multiple clinical studies for assessing burn wounds and diabetic foot ulcers. The company expects to submit applications for FDA, UKCA, and CE mark approval for its DeepView® System in 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.96%
Tags
Rhea-AI Summary
Spectral AI, Inc. (MDAI) appoints Erich Spangenberg as Chairman of the Executive Committee and Nominating and Corporate Governance Committee. Erich, the Company's largest shareholder, brings 40 years of experience in IP-related financings and is recognized as a top 50 IP strategist. Spectral AI received $251 million in non-dilutive funding from the US Government, and Erich aims to maximize shareholder value and reflect the intrinsic value of MDAI stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announced Q3 2023 financial results, affirming full-year revenue guidance for 2023 and 2024. The company highlighted progress in developing and commercializing its AI-Driven DeepView® System wound healing assessment technology. The system provides immediate wound healing potential assessment, with high accuracy for burn and diabetic foot ulcers. The company is preparing for the commercial launch of the DeepView® System as early as 2024, following regulatory approvals. Q3 2023 financial results overview showed a decline in R&D revenue, gross margin, and an increase in general & administrative expenses. The net loss was $(10.6) million, and cash and cash equivalents totaled $7.3 million as of September 30, 2023. The company reaffirmed its revenue guidance for full year 2023 and 2024, expecting 2024 revenue growth of approximately 60% from anticipated 2023 levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
-
Rhea-AI Summary
Spectral AI, Inc. will report financial results for Q3 2023 on November 13, 2023. A conference call to discuss the results will be held on November 14, 2023. Investors can access the webcast of the call on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.2%
Tags
Rhea-AI Summary
Spectral AI appoints Prof. Paul Chadwick as Executive VP of its UK subsidiary to expand the international market for its DeepView® wound imaging technology. Prof. Chadwick brings extensive experience in the medical devices and technology sectors, particularly in diabetic wound management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
Spectral AI, Inc.